HU
Hanyang University at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Hanyang University takes part in 3 sessions at ESMO 2026 in Madrid. Its program centres on lung cancer, from bispecific T-cell engager and CAR T-cell therapies in small cell lung cancer to treatment after first-line therapy stops working in non-small cell lung cancer. It also covers the biology and testing of tumours with ROS1 gene fusions.
| Organization | ESMO 2026 Attendance |
|---|---|
HU Hanyang University Seoul, Republic of Korea | |
Private university in Seoul, South Korea, with a college of medicine and university hospitals. | Chair Fri Oct 23 13:30–15:00 SCLC: Can we finally tackle it? Lung & thoracic cancers Talk Fri Oct 23 13:45–14:00 When and how to BiTE SCLC and CAR-T? Lung & thoracic cancers Satellite Fri Oct 23 18:15–19:45 AstraZeneca - Advancing excellence in lung cancer: New biomarkers, novel combinations, and changing standards of care Lung & thoracic cancersBiomarkers & precision oncology Satellite Fri Oct 23 18:15–18:20 Welcome and introductions Lung & thoracic cancersBiomarkers & precision oncology Satellite Fri Oct 23 19:00–19:15 Transforming the NSCLC landscape to improve outcomes after progression on 1L therapy Lung & thoracic cancersBiomarkers & precision oncology Talk Sun Oct 25 18:45–19:05 Biology insights and optimal testing strategies for patients with ROS1-fused solid tumours Lung & thoracic cancers |
Instantly find 20 buyers from Hanyang University
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction